|
Gene: NAV1 |
Gene summary for NAV1 |
Gene summary. |
Gene information | Species | Human | Gene symbol | NAV1 | Gene ID | 89796 |
Gene name | neuron navigator 1 | |
Gene Alias | POMFIL3 | |
Cytomap | 1q32.1 | |
Gene Type | protein-coding | GO ID | GO:0000226 | UniProtAcc | Q8NEY1 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
89796 | NAV1 | NEOLP-3 | Human | Oral cavity | NEOLP | 9.06e-03 | 1.75e-01 | -0.0191 |
89796 | NAV1 | SYSMH1 | Human | Oral cavity | OSCC | 1.18e-66 | 1.14e+00 | 0.1127 |
89796 | NAV1 | SYSMH2 | Human | Oral cavity | OSCC | 2.49e-13 | 3.70e-01 | 0.2326 |
89796 | NAV1 | SYSMH3 | Human | Oral cavity | OSCC | 3.22e-27 | 6.35e-01 | 0.2442 |
89796 | NAV1 | SYSMH5 | Human | Oral cavity | OSCC | 7.24e-04 | 1.38e-01 | 0.0647 |
89796 | NAV1 | HTA12-15-2 | Human | Pancreas | PDAC | 4.41e-04 | 2.73e-01 | 0.2315 |
89796 | NAV1 | HTA12-23-1 | Human | Pancreas | PDAC | 5.20e-08 | 7.03e-01 | 0.3405 |
89796 | NAV1 | HTA12-25-1 | Human | Pancreas | PDAC | 3.52e-06 | 4.60e-01 | 0.313 |
89796 | NAV1 | HTA12-26-1 | Human | Pancreas | PDAC | 9.17e-18 | 7.31e-01 | 0.3728 |
89796 | NAV1 | HTA12-29-1 | Human | Pancreas | PDAC | 5.38e-40 | 7.69e-01 | 0.3722 |
89796 | NAV1 | HTA12-32-1 | Human | Pancreas | PDAC | 4.23e-05 | 9.56e-01 | 0.3624 |
89796 | NAV1 | P1_cSCC | Human | Skin | cSCC | 1.96e-16 | 6.32e-01 | 0.0292 |
89796 | NAV1 | P2_cSCC | Human | Skin | cSCC | 8.43e-03 | 3.07e-01 | -0.024 |
89796 | NAV1 | P4_cSCC | Human | Skin | cSCC | 1.54e-11 | 3.30e-01 | -0.00290000000000005 |
89796 | NAV1 | P10_cSCC | Human | Skin | cSCC | 1.50e-10 | 6.07e-01 | 0.1017 |
89796 | NAV1 | male-WTA | Human | Thyroid | PTC | 4.39e-26 | 3.14e-01 | 0.1037 |
89796 | NAV1 | PTC01 | Human | Thyroid | PTC | 5.41e-08 | 2.10e-01 | 0.1899 |
89796 | NAV1 | PTC05 | Human | Thyroid | PTC | 6.73e-21 | 6.31e-01 | 0.2065 |
89796 | NAV1 | PTC06 | Human | Thyroid | PTC | 2.39e-47 | 1.09e+00 | 0.2057 |
89796 | NAV1 | PTC07 | Human | Thyroid | PTC | 2.35e-20 | 4.24e-01 | 0.2044 |
Page: 1 2 3 4 5 |
Transcriptomic changes along malignancy continuum. |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | |
Colorectum | SER | |
Colorectum | MSS | |
Colorectum | MSI-H | |
Colorectum | FAP |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00017643 | Oral cavity | NEOLP | neuron migration | 31/2005 | 156/18723 | 4.96e-04 | 4.40e-03 | 31 |
Page: 1 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
NAV1 | SNV | Missense_Mutation | novel | c.3223N>A | p.Glu1075Lys | p.E1075K | Q8NEY1 | protein_coding | deleterious(0) | probably_damaging(0.94) | TCGA-3C-AALI-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unspecific | Poly E | Complete Response |
NAV1 | SNV | Missense_Mutation | novel | c.2251N>A | p.Asp751Asn | p.D751N | Q8NEY1 | protein_coding | tolerated(0.07) | benign(0.222) | TCGA-5L-AAT1-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Hormone Therapy | letrozol | SD |
NAV1 | SNV | Missense_Mutation | novel | c.3127A>G | p.Met1043Val | p.M1043V | Q8NEY1 | protein_coding | deleterious(0.01) | benign(0.237) | TCGA-A7-A5ZX-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | doxorubicin | CR |
NAV1 | SNV | Missense_Mutation | c.1781N>T | p.Ser594Leu | p.S594L | Q8NEY1 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-A8-A06Q-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD | |
NAV1 | SNV | Missense_Mutation | c.1112N>T | p.Arg371Leu | p.R371L | Q8NEY1 | protein_coding | deleterious(0.01) | benign(0.175) | TCGA-A8-A07I-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Chemotherapy | 5-fluorouracil | CR | |
NAV1 | SNV | Missense_Mutation | novel | c.4262N>G | p.Leu1421Arg | p.L1421R | Q8NEY1 | protein_coding | deleterious(0.01) | possibly_damaging(0.81) | TCGA-A8-A0A4-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | tamoxiphen | CR |
NAV1 | SNV | Missense_Mutation | rs756027772 | c.1754N>A | p.Arg585His | p.R585H | Q8NEY1 | protein_coding | tolerated(0.32) | benign(0.031) | TCGA-AC-A3YJ-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD |
NAV1 | SNV | Missense_Mutation | c.3314N>G | p.Ser1105Cys | p.S1105C | Q8NEY1 | protein_coding | deleterious(0) | probably_damaging(0.982) | TCGA-AN-A0XW-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD | |
NAV1 | SNV | Missense_Mutation | rs765580417 | c.2957N>T | p.Pro986Leu | p.P986L | Q8NEY1 | protein_coding | tolerated(0.11) | benign(0.003) | TCGA-AO-A03R-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD |
NAV1 | SNV | Missense_Mutation | c.510N>T | p.Lys170Asn | p.K170N | Q8NEY1 | protein_coding | deleterious(0.04) | possibly_damaging(0.525) | TCGA-B6-A0I8-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | PD |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |